In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.

Shares of Gilead Sciences Inc. GILD shed 1.08% to $114.74 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.22% to 5,778.15 ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other stocks that analysts think will go up. The S&P 500 index touched an all-time high ...

Has Gilead Sciences (GILD) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Gilead Sciences is a member of the Medical sector.

Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives ...

Sapio Sciences, the science-aware TM lab informatics platform, today announced key leadership appointments to accelerate drug discovery and redefine AI-driven lab informatics. With the appointment ...

Foster City: Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir-the company’s twice-yearly ...

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--#GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health ...